21 companies in the research record · 11 Tracker · 10 Scouts

I want to live longer. And I want to generate a return by investing in companies working to make that possible.

That’s why I started the Longevity Tracker.

Over the next five years, I’m looking for longevity biotechs that can pass two tests: credible science with the potential to extend healthy life, and a business that makes sense as an investment.

Passing one test isn’t enough.

A company can have exciting science and run out of money. A treatment can succeed while shareholders face heavy dilution. And even a promising business can be a poor investment at the wrong price.

My goal is to find companies where both the science and the investment case hold up—and generate a return if I get those decisions right.

I’ll share the evidence, the risks, and what changes my mind along the way.

This is educational research, not personalized investment or medical advice. Biotech investments can lose their entire value. Research progress does not establish that a treatment extends human life.

Since May, I’ve been assessing longevity companies using the same 25-question framework and recording my decisions with dates.

So far, 21 companies have entered the research record:

As of the record’s September 24, 2026 cutoff, five companies had reached documented development milestones since inclusion. One had raised a financing warning. One Scout had missed its main trial goal.

The setbacks stay in the record.

I want to return to those original assessments and ask: What did I get right? What did I miss? What should I change?

Development milestones are not investment returns. And these early outcomes don’t establish that my framework predicts success. They give us something concrete to examine as the project develops.

Insilico Medicine, ProKidney, and BioAge Labs hold the highest recorded scores within the Tracker list. Those scores reflect my research judgments at the time of assessment—not predictions of treatment success or financial results.

Starting with the highest-scoring company, I’ll revisit the evidence and explain whether my assessment still holds up.

See the 21 companies in my research record →

Ownership disclosure: I personally own shares of Repair Biotechnologies, which is included in the Tracker. That gives me a financial interest in a company I cover.

I want to know what happens after the exciting announcement.

Does promising early research hold up in a larger trial? Can the company afford its next stage of development? Does a financing deal strengthen the business while leaving existing shareholders with a smaller stake?

Those questions connect my two goals: more healthy years and investment returns.

Five years is the horizon for this project. It gives me time to follow meaningful developments and revisit my reasoning. It isn’t a deadline for drug approval or a promise of investment success. Some programs will take longer. Others may fail much sooner.

At each step, I’ll ask:

Has the evidence improved? Can the company finance what comes next? Does the valuation make sense?

My personal goal is to earn a return. The Tracker records research assessments and company developments; its scores and milestones do not measure portfolio performance.

My 25 questions are organized around five areas:

The science
What biological process does the company target? How strong is the supporting research, and what could undermine the approach?

Human evidence
What has actually been tested in people? What did the study show—and what remains unproven?

The team
Have these people developed treatments, run trials, and handled the challenges this company faces?

The money
How much cash is available? What could the next stages cost? What financing might be needed, and how does the valuation compare with the evidence?

The market
If the treatment succeeds, who would use it, who would pay, and what alternatives would it face?

I want to understand what could make each company valuable, alongside the reasons it could fail.

Companies selected for closer research enter the Tracker. Others remain Scouts while I follow unresolved questions.

Original assessments remain in the record. Later developments, corrections, and reassessments are added as dated updates.

My next edition will revisit the highest-scoring company in the record.

I’ll explain what the company is trying to do, examine the evidence behind its score, and look at the financing and valuation questions that matter to the investment case.

That first complete assessment will be free, so you can see exactly how I work.

After that, free editions will continue to include plain-English science explainers, selected company updates, and highlights from the project.

The planned paid subscription will provide full company assessments, detailed scores and revisions, and access to the complete Tracker and research archive. I’ll share the price and exact benefits before subscriptions open.

The public summary will continue to show progress and setbacks.

After the highest-scoring company, which would you like me to revisit?

Reply with the company’s name—and, if you have one, the question you most want answered about it.

I’m doing this because the outcome matters to me personally. I want more healthy years with the people I love, and I want to earn a return from backing businesses working toward that future.

Finding those businesses takes more than an exciting headline. This newsletter is where I’ll share the work.

Explore the Longevity Tracker research record →

EverLife Capital publishes general educational research, not personalized investment or medical advice. The Longevity Tracker is a research project, not a fund, and holds no investor money. Tracker and Scout classifications reflect the author’s research judgments; they do not establish suitability for any reader or predict clinical or financial outcomes. Personal investment goals are not forecasts or guarantees. Private-company shares may be difficult or impossible to sell.

The author personally owns shares of Repair Biotechnologies, included in the Tracker, and Yuva Biosciences, not included in the Tracker. EverLife has received no compensation for coverage from the biotechnology companies named in this issue.